HK1212250A1 - Antiviral compounds, unit dosage form comprising said compounds and use thereof - Google Patents

Antiviral compounds, unit dosage form comprising said compounds and use thereof

Info

Publication number
HK1212250A1
HK1212250A1 HK16100369.5A HK16100369A HK1212250A1 HK 1212250 A1 HK1212250 A1 HK 1212250A1 HK 16100369 A HK16100369 A HK 16100369A HK 1212250 A1 HK1212250 A1 HK 1212250A1
Authority
HK
Hong Kong
Prior art keywords
compounds
dosage form
unit dosage
antiviral
antiviral compounds
Prior art date
Application number
HK16100369.5A
Other languages
English (en)
Chinese (zh)
Inventor
Yarlagadda Sudhakara Babu
Pooran Chand
Shanta Bantia
Shane Arnold
John Michael Kilpatrick
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38169715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1212250(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2006/013535 external-priority patent/WO2007117241A1/en
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of HK1212250A1 publication Critical patent/HK1212250A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK16100369.5A 2006-02-13 2016-01-14 Antiviral compounds, unit dosage form comprising said compounds and use thereof HK1212250A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77274806P 2006-02-13 2006-02-13
PCT/US2006/013535 WO2007117241A1 (en) 2006-04-12 2006-04-12 Intramuscular antiviral treatments

Publications (1)

Publication Number Publication Date
HK1212250A1 true HK1212250A1 (en) 2016-06-10

Family

ID=38169715

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100369.5A HK1212250A1 (en) 2006-02-13 2016-01-14 Antiviral compounds, unit dosage form comprising said compounds and use thereof

Country Status (11)

Country Link
EP (1) EP1986626A1 (ru)
JP (3) JP2009538822A (ru)
KR (9) KR20160129105A (ru)
AU (2) AU2007215156A1 (ru)
BR (1) BRPI0707769A2 (ru)
CA (1) CA2642260C (ru)
EA (1) EA025483B1 (ru)
HK (1) HK1212250A1 (ru)
MX (2) MX2008010394A (ru)
MY (1) MY166063A (ru)
WO (1) WO2007095218A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1986626A1 (en) * 2006-02-13 2008-11-05 Biocryst Pharmaceuticals Inc. Intravenous antiviral treatments
CN101367750B (zh) * 2007-08-14 2012-05-23 中国人民解放军军事医学科学院毒物药物研究所 (1s,2s,3s,4r)-3-[(1s)-1-乙酰氨-2-乙基-丁基]-4-胍基-2-羟基-环戊基-1-羧酸水合物及其医药用途
KR20220033561A (ko) 2020-09-07 2022-03-17 주식회사 경보제약 페라미비르 화합물을 포함하는 프리믹스 제형의 제약학적 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT933993E (pt) * 1996-06-14 2006-10-31 Biocryst Pharm Inc Compostos de ciclopentano substituidos, uteis como inibidores de neuraminidase
DE69840674D1 (de) * 1997-12-17 2009-04-30 Biocryst Pharm Inc Substituierte cyclopentan- und cyclopenten-verbindungen als neuraminidase-blocker
GB0015324D0 (en) * 2000-06-22 2000-08-16 Biota Scient Management Medicaments
EP1986626A1 (en) * 2006-02-13 2008-11-05 Biocryst Pharmaceuticals Inc. Intravenous antiviral treatments

Also Published As

Publication number Publication date
MY166063A (en) 2018-05-23
JP6073202B2 (ja) 2017-02-01
KR20160129105A (ko) 2016-11-08
KR20210076189A (ko) 2021-06-23
JP2015180695A (ja) 2015-10-15
JP2009538822A (ja) 2009-11-12
KR102475176B1 (ko) 2022-12-07
KR102267754B1 (ko) 2021-06-23
MX2020002008A (es) 2020-07-13
WO2007095218A1 (en) 2007-08-23
EA025483B1 (ru) 2016-12-30
KR20190072681A (ko) 2019-06-25
KR101992585B9 (ko) 2022-09-20
KR20230003248A (ko) 2023-01-05
EP1986626A1 (en) 2008-11-05
CA2642260C (en) 2016-08-09
KR102323339B1 (ko) 2021-11-08
MX2008010394A (es) 2009-01-12
AU2013216632A1 (en) 2013-08-29
AU2013216632B2 (en) 2016-09-01
KR20140132778A (ko) 2014-11-18
KR20180024027A (ko) 2018-03-07
EA200870263A1 (ru) 2009-06-30
CA2642260A1 (en) 2007-08-23
KR20200143519A (ko) 2020-12-23
AU2007215156A1 (en) 2007-08-23
KR20080096829A (ko) 2008-11-03
JP2013256527A (ja) 2013-12-26
KR20210135632A (ko) 2021-11-15
BRPI0707769A2 (pt) 2011-05-10
KR101992585B1 (ko) 2019-06-25
KR102194015B1 (ko) 2020-12-22

Similar Documents

Publication Publication Date Title
IL251539A0 (en) Single pharmaceutical dosage form
ZA201000185B (en) 17beta-cyano-18a-homo-19-nor-androst-4-ene derivative,use thereof and medicaments containing said derivative
ME01550B (me) Farmaceutski dozni oblici
IL192565A0 (en) Medicament for topical use
GB0625659D0 (en) Therapeutic compounds and their use
ZA200902189B (en) Phenylpropionamide compounds and the use thereof
EP2079313A4 (en) ANTIMICROBIAL AND ANTIVIRAL COMPOUNDS AND METHOD FOR THEIR USE
GB0513984D0 (en) Dosage form
IL194899A0 (en) Amino-ethyl-amino-aryl (aeaa) compounds and their use
HK1128154A1 (en) Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments
GB0423964D0 (en) Dosage form
IL193384A0 (en) Substituted prolinamides, their preparation and their use as pharmaceuticals
GB0616794D0 (en) Solid dosage form
ZA201000187B (en) 17b-cyano-19-nor-androst-4-ene derivative,use thereof and medicaments containing said derivative
EP2069371A4 (en) ORGANO ARSENOXIDE COMPOUNDS AND THEIR USE
HK1212250A1 (en) Antiviral compounds, unit dosage form comprising said compounds and use thereof
GB0512453D0 (en) Dosage unit
EP2192122A4 (en) Dithiolopyrrolone compounds and their preparation and use
GB0613031D0 (en) Medicaments
GB0615064D0 (en) Medicament
ZA201000186B (en) 17b-cyano-19-androst-4-ene derivative,use thereof and medicaments containing said derivative
IL191892A0 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
ZA200809732B (en) Single use syringe
GB0615814D0 (en) Medicament
GB0614538D0 (en) Therapeutic Compounds And Their Use